ClinicalTrials.gg

Program

JNJ-95597528

A development code.

Its studies are mostly in Dermatitis, Atopic · Asthma, led by Johnson & Johnson.

Furthest: phase 2, since Nov 14, 20252 company-led studies, 2 open or runningNext primary completion: Nov 19, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson22 open or runningphase 2since Nov 14, 2025Nov 14, 2025Nov 19, 2026phase 2 · NCT07230860
  • Named in Johnson & Johnson’s own pipeline as JNJ-7528, phase 2, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 14, 2025First study: phase 2 study in Dermatitis, AtopicFirst studyNCT07230860 · 189 enrolled · United States, Argentina, Brazil and more
  2. Jul 31, 2026Phase 2 study in AsthmaNCT07746687 · 440 planned · United States, Argentina, China and more

Ahead

  1. Nov 19, 2026Primary completion: phase 2 study in Dermatitis, AtopicNCT07230860
  2. Sep 11, 2029Primary completion: phase 2 study in AsthmaNCT07746687

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07746687Asthma · United States, Argentina, China and more2RecruitingSep 11, 2029440
NCT07230860Dermatitis, Atopic · United States, Argentina, Brazil and more2Active, not recruitingNov 19, 2026189

How it is read

Names in the registry

  • “JNJ-95597528”, 2 entries

Codes read as this program: JNJ95597528.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
JNJ-95597528 (Johnson & Johnson): development program | ClinicalTrials.gg